us Elastography and us Doppler in Differentiating Breast Masses

September 29, 2020 updated by: Asmaa Sayed Mohamed Abd Elsamie, Assiut University

Comparative Study of US Elastography and Color Doppler US in Differentiating Breast Masses in Correlation to Histopathology

The aim of this study is to compare the diagnostic performance of grey scale US , US elastography & color Doppler US in differentiating breast masses comparable with histopathology as a gold standard.

Study Overview

Status

Unknown

Detailed Description

Breast cancer is the most fre¬quently diagnosed cancer and the chief cause of cancer death among women worldwide, with an es¬timated 1.7 million cases.

Breast cancer alone accounts for 25% of all cancer cases and 15% of all cancer deaths among females .so, Its high incidence has led to research on new diagnostic imaging techniques for early diagnosis and to improve patient's mortality rate[1].

Application of imaging techniques together with other investigation would help clinical decision making. the most important factor in reducing mortality of certain cancers is an early diagnosis of cancer via screening based on imaging[2].

US is an accurate method for detection of breast masses ; however, US has a low accuracy in differentiating between benign from malignant breast masses . US could suggest a malignancy likelihood criteria of a breast mass, such as hypoechogenicity, irregular margins, microcalcifications, increased vascularity by Doppler and us elastography [3].

Ultrasound elastography provides a non-invasive evaluation of the "stiffness" of a lesion. Recent studies show that ultrasonographic elastogra¬phy (USE) provides higher diagnostic accuracy together with Doppler application compared with conventional B-mode ultrasonography during breast cancer diagnosis, which eventually helps to reduce false-positive results (ie, increased specificity) and therefore is useful in avoiding breast biopsy[4].

US elastography has been used to detect the nature of breast lesions , by measuring the tissue stiffness non invasively. It depends on tissue deformation strain that is caused by external compression. it is complementary to gray scale findings particularly in lesions with indeterminate US findings, also US elastography could be used to guide the follow up of leisons diagnosed as benign at ( FNA) fine needle aspiration.[5][6]

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients will subjected to :

Full history taking, clinical examination by referring physician . Then the patient will be examined by Gray scale US , doppler and elastography at Radiology department.

On Gray scale:Echogenicity of the mass with respect to normal breast parenchyma, diameter A/T ,margins and calcifications.

While on Color Doppler, to describe the vascular patterns. Masses and axillary lymph nodes (if detected) will be identified as nonvascular or vascular (peripheral, central, or mix).

(A) Strain elastography Color coding is classified into 5 groups according to the Ueno classification, score one (softest component) and score five (hardest component) .

(B) Shear wave elastography A ROI rectangular box was adjusted on the observed target lesion including sufficient amount of surrounding healthy breast tissue.

Description

Inclusion Criteria:

  • patients with breast masses referred to our department of diagnostic radiology for radiological assessment.

Exclusion Criteria:

Patients with purely cystic lesions on conventional breast ultrasound. Breast implant. Superficial lesions (>5 mm deep to skin surface).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
comparison between us elastography and doppler us of breast masses with the histopathology of the specimens
Time Frame: baseline
comparitive study between us elastography and doppler us of breast masses in differentiating breast masses
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

September 1, 2021

Primary Completion (Anticipated)

September 1, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

September 29, 2020

First Submitted That Met QC Criteria

September 29, 2020

First Posted (Actual)

October 5, 2020

Study Record Updates

Last Update Posted (Actual)

October 5, 2020

Last Update Submitted That Met QC Criteria

September 29, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • breast US elastography

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Lump (Malignant)

Subscribe